Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Who we help

As the trusted partner to the top 50 global pharmaceutical companies and top 10 contract research organizations, our pharmaceutical data, insights, and analytics are used by businesses operating in all areas of the industry.

Our Specialties

For pharmaceutical companies

Bring game-changing drugs to market more efficiently using our insight and analysis. We’ll help you beat the competition and improve healthcare and patient outcomes.

For contract research organizations

We can help position your organization to win more business and enhance your drug development services. You’ll make better-informed, data-driven decisions while bidding on and implementing clinical trials.

For consultancies

Focus on your clients and expand your business opportunities with Pharma Intelligence. We’ll help you build a complete picture of the fast-changing pharmaceutical market with our insight and expertise.

For marketing agencies

You need to understand and communicate complex information simply and persuasively, often across a variety of channels. We can help with branding, multi-channel communication and more.

For the medtech sector

Your trusted source for industry data, analysis, opinion and news. Access the information you need to inform deal making and business cases for product development and quality control and compliance.

Relevant products

Trialtrove: gold standard clinical trials intelligence

Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.

Key benefits:

Curated by experts
Clinical trial landscape view
Ask-the-Analyst™

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

Pink Sheet

EMA Issues Guidance On Compassionate Use Of Remdesivir For COVID-19

Recommendations from the European Medicines Agency explain the conditions under which early access to remdesivir could be given through compassionate use programs.

Topic Coronavirus

View article
Pink Sheet

COVID-19 Vaccines: Ex-FDA Leaders Urge High Bar For Emergency Use Authorization

Eschewing the standard approval mechanisms for COVID-19 vaccines is likely only appropriate in very limited high-risk populations, unless clinical efficacy outcomes are available, former FDA leaders say.

Topic Coronavirus

View article
Scrip

Coronavirus Update: Drug Shortages On Horizon, Firms Offer Medical Staff For The Fight, More Studies Start

Fears over shortages of drugs needed for ventilated patients rise, while Merck & Co, Pfizer and Lilly allow their medics to volunteer, and attention turns to beta-interferon products and NK cell therapies to fight the virus.

Topic Coronavirus

View article
Scrip

Amgen, Adaptive Partner In COVID-19 Neutralizing Antibody R&D Effort

The companies are combining their technologies to seek neutralizing antibody therapeutics that could prevent or treat COVID-19, building on their previous partnership in monitoring minimal residual disease in blood cancers.

Topic Coronavirus

View article
Generics Bulletin

Coronavirus Puts The Brakes On Mylan-Upjohn Merger

Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.

Topic Coronavirus

View article
Generics Bulletin

Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

Topic Coronavirus

View article
Scrip

Amgen, Adaptive Partner In COVID-19 Neutralizing Antibody R&D Effort

The companies are combining their technologies to seek neutralizing antibody therapeutics that could prevent or treat COVID-19, building on their previous partnership in monitoring minimal residual disease in blood cancers.

Topic Coronavirus

View article
Scrip

Coronavirus Update: Drug Shortages On Horizon, Firms Offer Medical Staff For The Fight, More Studies Start

Fears over shortages of drugs needed for ventilated patients rise, while Merck & Co, Pfizer and Lilly allow their medics to volunteer, and attention turns to beta-interferon products and NK cell therapies to fight the virus.

Topic Coronavirus

View article
Pharmaprojects

Pharma RD Annual Review 2020 Infographic

Using new, granular data from Pharmaprojects, part of the Citeline suite of tools, this infographic will explore: The 2020 Pipeline by Phase Top Companies Mechanisms and Targets Types of Pipeline Drugs

Topic Research Drug Development Landscape Drug Review

View infographic
Pharmaprojects

Pharma RD Annual Review 2020 Whitepaper

Using the new, granular datapoints in Pharmaprojects, Senior Director Ian Lloyd presents his expert insights into pharma’s R&D activities over the past year and what they may mean for the pipeline during the year to come. The 27th instalment of the Annual Review, this version takes advantage of improvements to Pharmaprojects’ data granularity to bring you details on pharma R&D trends

Topic Drug Development Landscape Drug Review Research

View white paper
Pink Sheet

UK MHRA Relaxes GMP Rules For Drugs Imported From Third Countries During COVID-19 Outbreak

The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.

View article
Pink Sheet

Biopharma, Payers Seek National Guidelines For Prescribing Potential COVID-19 Drugs

Guidelines for US health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.

Topic Coronavirus

View article
Scrip

Moderna Not Immune To COVID-19 Effects On Trials

Company suspends enrolment to trials as coronavirus travel restrictions bite.

Topic Coronavirus

View article
Scrip

Coronavirus Update: Can IL-6 Drugs Cut Deaths? Kevzara Trials Start In Worst Hit Countries

News from around the biopharma sector and its efforts to meet the challenges posed by the coronavirus pandemic.

Topic Coronavirus

View article
Skipta

Driving Efficiency in Pharma Marketing

Making the most of today’s pharma marketing budgets can be tricky: you’re expected to deliver more, often with fewer resources. Explore the strategies most effective for getting your product or brand in front of the right healthcare professionals (HCPs) in this free white paper from Skipta.

View article